Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia

P. P. Gleason, W. N. Kapoor, R. A. Stone, J. R. Lave, D. S. Obrosky, R. Schulz, D. E. Singer, C. M. Coley, T. J. Marrie and M. J. Fine
Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pa, USA.

CONTEXT: The American Thoracic Society (ATS) published guidelines based on expert opinion and published data--but not clinically derived or validated--for treating adult outpatients with community-acquired pneumonia. OBJECTIVE: To compare medical outcomes and antimicrobial costs for patients whose antimicrobial therapy was consistent or inconsistent with ATS guidelines. DESIGN: Multicenter, prospective cohort study. SETTING: Emergency departments, medical clinics, and practitioner offices affiliated with 3 university hospitals, 1 community teaching hospital, and 1 health maintenance organization. PARTICIPANTS: A total of 864 immunocompetent, adult outpatients with community-acquired pneumonia: 546 aged 60 years or younger with no comorbidity and 318 older than 60 years or with 1 comorbidity or more. MAIN OUTCOME MEASURES: Patients' antimicrobial therapy was classified as being consistent or inconsistent with the ATS guidelines. Mortality, subsequent hospitalization, medical complications, symptom resolution, return to work and usual activities, health-related quality of life, and antimicrobial costs were compared among those treated consistently or inconsistently with the guidelines. RESULTS: Outpatients aged 60 years or younger with no comorbidity who were prescribed therapy consistent with ATS guidelines (ie, erythromycin with some exceptions) had 3-fold lower antimicrobial costs ($5.43 vs $18.51; P<.001) and no significant differences in medical outcomes. Outpatients older than 60 years or with 1 comorbidity or more who were prescribed therapy consistent with ATS guidelines (ie, second-generation cephalosporin, sulfamethoxazole-trimethoprim, or beta-lactam and beta-lactamase inhibitor with or without a macrolide) had 10-fold higher antimicrobial costs ($73.50 vs $7.50; P<.001); despite trends toward higher mortality and subsequent hospitalization, no significant differences in medical outcomes were observed. CONCLUSION: Our findings support the use of erythromycin as recommended by the ATS guidelines for outpatients aged 60 years or younger with no comorbidity. Although the antimicrobial therapy recommended in outpatients older than 60 years or with 1 comorbidity or more is more costly, this observational study provides no evidence of improved medical outcomes in the small subgroup who received ATS guideline-recommended therapy.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Impact of a Multidisciplinary Approach to Guideline Implementation in Diabetic Ketoacidosis
Volkova et al.
American Journal of Medical Quality 2008;23:47-55.
ABSTRACT  

Comparison of {beta}-Lactam and Macrolide Combination Therapy versus Fluoroquinolone Monotherapy in Hospitalized Veterans Affairs Patients with Community-Acquired Pneumonia
Lodise et al.
Antimicrob. Agents Chemother. 2007;51:3977-3982.
ABSTRACT | FULL TEXT  

Economic evaluation of adherence to treatment guidelines in nonintensive care pneumonia
Menendez et al.
Eur Respir J 2007;29:751-756.
ABSTRACT | FULL TEXT  

Long-term Symptom Recovery and Health-Related Quality of Life in Patients With Mild-to-Moderate-Severe Community-Acquired Pneumonia.
el Moussaoui et al.
Chest 2006;130:1165-1172.
ABSTRACT | FULL TEXT  

Does Guideline Adherence for Empiric Antibiotic Therapy Reduce Mortality in Community-acquired Pneumonia?
Aujesky and Fine
Am. J. Respir. Crit. Care Med. 2005;172:655-656.
FULL TEXT  

Interventions to Improve Treatment of Respiratory Infections in Ambulatory Managed-Care Patients
Raebel
The Annals of Pharmacotherapy 2005;39:699-705.
ABSTRACT | FULL TEXT  

Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia
Wasserfallen et al.
Eur Respir J 2004;24:644-648.
ABSTRACT | FULL TEXT  

Expectorated Sputum for Community-Acquired Pneumonia: A Sacred Cow
Madison and Irwin
Arch Intern Med 2004;164:1725-1727.
FULL TEXT  

Atypical pathogens and respiratory tract infections
Blasi
Eur Respir J 2004;24:171-182.
ABSTRACT | FULL TEXT  

Development and validation of a short questionnaire in community acquired pneumonia
El Moussaoui et al.
Thorax 2004;59:591-595.
ABSTRACT | FULL TEXT  

Guidelines for Empiric Antimicrobial Prescribing in Community-Acquired Pneumonia
File et al.
Chest 2004;125:1888-1901.
ABSTRACT | FULL TEXT  

A population-based study of the costs of care for community-acquired pneumonia
Bartolome et al.
Eur Respir J 2004;23:610-616.
ABSTRACT | FULL TEXT  

Current Management Issues Associated with Community-Acquired Pneumonia
Cregin
Journal of Pharmacy Practice 2003;16:324-334.
ABSTRACT  

Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations
Zhanel et al.
J Antimicrob Chemother 2003;52:83-88.
ABSTRACT | FULL TEXT  

Antibiotic Therapy for Ambulatory Patients With Community-Acquired Pneumonia in an Emergency Department Setting
Malcolm and Marrie
Arch Intern Med 2003;163:797-802.
ABSTRACT | FULL TEXT  

The Contribution of Blood Cultures to the Clinical Management of Adult Patients Admitted to the Hospital With Community-Acquired Pneumonia: A Prospective Observational Study
Campbell et al.
Chest 2003;123:1142-1150.
ABSTRACT | FULL TEXT  

Case Study: Administrative Data Versus Corrected Administrative Data
Price et al.
American Journal of Medical Quality 2003;18:38-45.
ABSTRACT  

Pharmacodynamic Modeling of Clarithromycin against Macrolide-Resistant [PCR-Positive mef(A) or erm(B)] Streptococcus pneumoniae Simulating Clinically Achievable Serum and Epithelial Lining Fluid Free-Drug Concentrations
Noreddin et al.
Antimicrob. Agents Chemother. 2002;46:4029-4034.
ABSTRACT | FULL TEXT  

Respiratory infections: Proceedings of the Eighth Liverpool Tropical School Bayer Symposium of Microbial Disease held on 3 February 2001
CANT et al.
J Med Microbiol 2002;51:903-914.
FULL TEXT  

The Community-Acquired Pneumonia Symptom Questionnaire* : A New, Patient-Based Outcome Measure To Evaluate Symptoms in Patients With Community-Acquired Pneumonia
Lamping et al.
Chest 2002;122:920-929.
ABSTRACT | FULL TEXT  

Severe Community-acquired Pneumonia: Use of Intensive Care Services and Evaluation of American and British Thoracic Society Diagnostic Criteria
Angus et al.
Am. J. Respir. Crit. Care Med. 2002;166:717-723.
ABSTRACT | FULL TEXT  

Influence of Deviation From Guidelines on the Outcome of Community-Acquired Pneumonia*
Menendez et al.
Chest 2002;122:612-617.
ABSTRACT | FULL TEXT  

Community-acquired pneumonia guidelines: much guidance, but not much evidence
Woodhead
Eur Respir J 2002;20:1-3.
FULL TEXT  

Treatment of community-acquired lower respiratory tract infections in adults
Ortqvist
Eur Respir J 2002;20:40S-53s.
ABSTRACT | FULL TEXT  

Hospitalized Community-acquired Pneumonia in the Elderly . Age- and Sex-related Patterns of Care and Outcome in the United States
KAPLAN et al.
Am. J. Respir. Crit. Care Med. 2002;165:766-772.
ABSTRACT | FULL TEXT  

Relationships Between Authors of Clinical Practice Guidelines and the Pharmaceutical Industry
Choudhry et al.
JAMA 2002;287:612-617.
ABSTRACT | FULL TEXT  

Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence
Ball et al.
J Antimicrob Chemother 2002;49:31-40.
ABSTRACT | FULL TEXT  

Ambulatory antimicrobial use: the value of an outcomes registry
Nathwani and Tice
J Antimicrob Chemother 2002;49:149-154.
ABSTRACT | FULL TEXT  

BTS Guidelines for the Management of Community Acquired Pneumonia in Adults
Thorax 2001;56:iv1-64.
FULL TEXT  

Clinical Evaluation of the Management of Community-Acquired Pneumonia by General Practitioners in France
Fantin et al.
Chest 2001;120:185-192.
ABSTRACT | FULL TEXT  

Guidelines for the Management of Adults with Community-acquired Pneumonia . Diagnosis, Assessment of Severity, Antimicrobial Therapy, and Prevention
Niederman et al.
Am. J. Respir. Crit. Care Med. 2001;163:1730-1754.
FULL TEXT  

Respiratory antibiotic use and Clostridium difficile infection: is it the drugs or is it the doctors?
WILCOX
Thorax 2000;55:633-634.
FULL TEXT  

Clinical Efficacy of Intravenous followed by Oral Azithromycin Monotherapy in Hospitalized Patients with Community-Acquired Pneumonia
Plouffe et al.
Antimicrob. Agents Chemother. 2000;44:1796-1802.
ABSTRACT | FULL TEXT  

Management of Community-Acquired Pneumonia in the Era of Pneumococcal Resistance: A Report From the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group
Heffelfinger et al.
Arch Intern Med 2000;160:1399-1408.
ABSTRACT | FULL TEXT  

A Guideline Implementation System Using Handheld Computers for Office Management of Asthma: Effects on Adherence and Patient Outcomes
Shiffman et al.
Pediatrics 2000;105:767-773.
ABSTRACT | FULL TEXT  

Evaluation of an Internet-based Decision-support System for Applying the ATS/CDC Guidelines for Tuberculosis Preventive Therapy
Dayton et al.
Med Decis Making 2000;20:1-6.
ABSTRACT  

Effect of Macrolides as Part of Initial Empiric Therapy on Length of Stay in Patients Hospitalized With Community-Acquired Pneumonia
Stahl et al.
Arch Intern Med 1999;159:2576-2580.
ABSTRACT | FULL TEXT  

Aging Lung and Possible Animal Models
Teramoto and Ouchi
Chest 1999;116:1145-1146.
FULL TEXT  

Commentary on the 1993 American Thoracic Society Guidelines for the Treatment of Community-Acquired Pneumonia
Campbell
Chest 1999;115:14S-18S.
ABSTRACT | FULL TEXT  

Screening for Helicobacter pylori and Nonsteroidal Anti-inflammatory Drug Use in Medicare Patients Hospitalized With Peptic Ulcer Disease
Hood et al.
Arch Intern Med 1999;159:149-154.
ABSTRACT | FULL TEXT  

Safely Increasing the Proportion of Patients With Community-Acquired Pneumonia Treated as Outpatients: An Interventional Trial
Atlas et al.
Arch Intern Med 1998;158:1350-1356.
ABSTRACT | FULL TEXT  

GUIDELINES EFFECTIVE FOR UNCOMPLICATED PNEUMONIA IN YOUNG PATIENTS
JWatch General 1997;1997:5-5.
FULL TEXT